A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following ...

Panelists discuss how patient education plays a crucial role in ensuring adherence to tyrosine kinase inhibitor (TKI) therapy by building trust through clear explanations of medications and expected ...

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine ...

A new study finds that statin use significantly improves survival outcomes in patients with chronic lymphocytic leukemia or ...

According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM ...

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...